Additional file 1 of Belgian rare diseases plan in clinical pathology: identification of key biochemical diagnostic tests and establishment of reference laboratories and financing conditions

Additional file 1: Figure S1. Analyses for which the mean annual volumes were not modified by the feasibility study results. Comparison of the volumes of tests reported by the Belgian laboratories of clinical pathology for 6 different years: group A (light grey bars, period before the presentation of the results of the feasibility study [data collected for 2014 and 2015]) versus group B (dark grey bars, period after the presentation of the results of the feasibility study [data collected for 2016 and 2017]) versus group C (black bars, period from RLs’ recognition [data collected for 2019 and 2... Mehr ...

Verfasser: Nathalie M. Vandevelde (10161891)
Pieter Vermeersch (4747938)
Katrien M. J. Devreese (10161894)
Marie-Françoise Vincent (301884)
Béatrice Gulbis (10161897)
François Eyskens (301890)
François Boemer (301887)
André Gothot (293096)
Viviane O. Van Hoof (10161900)
Carolien Bonroy (6420452)
Hedwig Stepman (10161903)
Geert A. Martens (10161906)
Xavier Bossuyt (564860)
Laurence Roosens (2295328)
Julie Smet (524213)
Hilde Laeremans (10161909)
Ilse Weets (3373913)
Jean-Marc Minon (396990)
Kris Vernelen (5706500)
Wim Coucke (301878)
Dokumenttyp: Image
Erscheinungsdatum: 2021
Schlagwörter: Medicine / Sociology / Science Policy / Biological Sciences not elsewhere classified / Rare diseases / Clinical pathology / Financing / Reference laboratories / Reimbursement codes / Expertise
Sprache: unknown
Permalink: https://search.fid-benelux.de/Record/base-28874969
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : https://doi.org/10.6084/m9.figshare.14053554.v1